| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target of Pradigastat sodium is diacylglycerol acyltransferase 1 (DGAT1), an enzyme that catalyzes the final step in triglyceride synthesis. By inhibiting DGAT1, it reduces triglyceride synthesis and absorption, leading to decreased postprandial triglyceride levels. It also inhibits BCRP and OAT transporters, which may contribute to its pharmacokinetic profile.
|
|---|---|
| ln Vitro |
In vitro, Pradigastat sodium inhibits DGAT1 enzymatic activity with an IC50 of 0.157 µM. It reduces triglyceride synthesis in intestinal cells and hepatocytes. It also inhibits BCRP and OAT transporters, which may affect drug absorption and distribution. Its selectivity for DGAT1 over DGAT2 has been established.
|
| ln Vivo |
In vivo, Pradigastat sodium reduces postprandial triglyceride levels in animal models and humans. It decreases chylomicron secretion and improves lipid profiles. It was evaluated in clinical trials for familial chylomicronemia syndrome. Its oral bioavailability supports once-daily dosing.
|
| Enzyme Assay |
For DGAT1 enzyme inhibition assays, microsomal fractions containing DGAT1 or recombinant enzyme are incubated with diacylglycerol and radiolabeled acyl-CoA in the presence of Pradigastat sodium. Triglyceride formation is measured by scintillation counting or TLC. IC50 values are determined from dose-response curves.
|
| Cell Assay |
For cellular assays, intestinal epithelial cells or hepatocytes are treated with Pradigastat sodium. Triglyceride synthesis is measured by radiolabeled precursor incorporation. Secretion of triglycerides or apoB-containing lipoproteins is quantified by ELISA. BCRP and OAT inhibition is assessed using fluorescent substrate transport assays.
|
| Animal Protocol |
For in vivo studies, mice or rats receive Pradigastat sodium orally before a lipid challenge. Postprandial triglyceride levels are measured in plasma by enzymatic assay. Chylomicron secretion is assessed by measuring triglyceride content in lymph or plasma. Blood samples are collected for pharmacokinetic analysis.
|
| References |
|
| Molecular Formula |
C25H23F3N3NAO2
|
|---|---|
| Molecular Weight |
477.46
|
| Exact Mass |
477.164
|
| CAS # |
956136-98-4
|
| Related CAS # |
956136-95-1 (free acid);956136-98-4 (sodium);
|
| PubChem CID |
53387034
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.392
|
| tPSA |
77.94
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
34
|
| Complexity |
637
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na+].FC(C1=CC=C(C=N1)NC1=CN=C(C=C1)C1C=CC(=CC=1)C1CCC(CC(=O)[O-])CC1)(F)F
|
| InChi Key |
MUZRGKSNUTWRAF-BHQIMSFRSA-M
|
| InChi Code |
InChI=1S/C25H24F3N3O2.Na/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33)/q+1/p-1/t16-,17-
|
| Chemical Name |
sodium 2-((1r,4r)-4-(4-(5-((6-(trifluoromethyl)pyridin-3-yl)amino)pyridin-2-yl)phenyl)cyclohexyl)acetate
|
| Synonyms |
Pradigastat sodium LCQ 908ABA LCQ-908LCQ-908ABA LCQ908LCQ908ABA LCQ 908
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0944 mL | 10.4721 mL | 20.9442 mL | |
| 5 mM | 0.4189 mL | 2.0944 mL | 4.1888 mL | |
| 10 mM | 0.2094 mL | 1.0472 mL | 2.0944 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.